This site uses cookies to improve your experience and to provide services and advertising. By continuing to browse, you agree to the use of cookies described in our Cookies Policy. You may change your settings at any time but this may impact on the functionality of the site. To learn more see our Cookies Policy.
Dublin: 14 °C Sunday 22 September, 2019

Early screening test for pre-eclampsia being developed by Irish startup

The bioscience company has received three-quarters of a million euro to develop what it calls “breakthrough blood test”.

Minister Seán Sherlock is shown how the blood test works.
Minister Seán Sherlock is shown how the blood test works.

AN IRISH BIOSCIENCE company has secured €750,000 to develop a test which could detect pre-eclampsia risk in pregnant women at an early stage of their pregnancy.

Pre-eclampsia can be a fatal condition and doesn’t generally make itself known until the second half of the term of pregnancy. At that time, the only treatment option should it escalate (the high blood pressure symptom can be incredibly dangerous for mother and baby) can be early delivery of the baby.

Irish start-up Metabolomic Diagnostic is developing a blood test called ‘PrePsia’ which it is hoped will detect women at high risk of developing pre-eclampsia, allowing for early treatment before the condition deteriorates.

Junior minister for research and innovation, Seán Sherlock, said that the investment from Enterprise Ireland, AIB Seed Capital Fund and SOSventures Ireland Fund is vital. He said:

This is an important investment, given the potential significance of this metabolomic diagnostic test, the results of which include saving lives.

There are currently 5,000 pregnant women from all over Europe involved in giving blood specimens to test Metabolomic Diagnostics technology.

The company is based in Little Island in Cork.

For those seeking further information, clarification and support on pre-eclampsia, visit, the website of the Pre-eclampsia Foundation, a registered charity and patient advocacy group.

Breast cancer patients who stop oral hormone therapy increase risk of recurrence>
Test made in Longford can help docs spot if you’re having a heart attack>

  • Share on Facebook
  • Email this article

About the author:

Read next: